- Home
- TDC vs EWTX Comparison
TDC vs EWTX Comparison
Compare TDC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | EWTX |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TDC | EWTX |
|---|---|---|
| Price | $35.17 | $46.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $34.78 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $2,156,000,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.44 | N/A |
| P/E Ratio | $10.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.83 | $12.31 |
| 52 Week High | $41.78 | $43.93 |
Technical Indicators
Market Signals| Indicator | TDC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.92 | 72.74 |
| Support Level | $29.21 | $28.27 |
| Resistance Level | $36.86 | N/A |
| Average True Range (ATR) | 1.58 | 2.50 |
| MACD | 0.36 | 0.52 |
| Stochastic Oscillator | 78.20 | 97.31 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.